Showing results (1-10 of 33) with videos related to
Sort By:
Pageof 4
BMC Medicine|December 8, 2016
Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors - assessment of intra-tumour heterogeneityViktoria Stühler, Jens BedkeCurrent Opinion in Urology|November 10, 2017
Immunotherapy for kidney cancer: status quo and the futureJens Bedke, Viktoria Stühler, Arnulf Stenzl, et al.Urologie (Heidelberg, Germany)|November 26, 2025
[Priapism: current status and new insights]Viktoria Stühler, Katharina Friederich, Richard Spallek, et al.Cancers|June 24, 2022
Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus NivolumabViktoria Stühler, Lisa Herrmann, Steffen Rausch, et al.Journal of Cancer Research and Clinical Oncology|July 30, 2022
Real world data on IO-based therapy for metastatic renal cell carcinomaViktoria Stühler, Lisa Herrmann, Steffen Rausch, et al.Urologia Internationalis|January 16, 2024
Hemangioma of the Urinary Bladder: A Brief Narrative Review of Their Diagnosis, Histology, and Treatment OptionsRadion Garaz, Viktoria Stühler, Arnulf Stenzl, et al.Expert Opinion on Biological Therapy|December 16, 2020
Enfortumab vedotin - next game-changer in urothelial cancerMoritz Maas, Viktoria Stühler, Simon Walz, et al.Expert Opinion on Biological Therapy|October 8, 2019
Immune checkpoint inhibition for the treatment of renal cell carcinomaViktoria Stühler, Jan Moritz Maas, Steffen Rausch, et al.Expert Opinion on Biological Therapy|May 15, 2020
An evaluation of avelumab for the treatment of genitourinary tumorsViktoria Stühler, Jan Moritz Maas, Simon Walz, et al.Expert Opinion on Biological Therapy|February 12, 2021
Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinomaViktoria Stühler, Steffen Rausch, Jan Moritz Maas, et al.Pageof 4